Your browser doesn't support javascript.
loading
Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension.
Staessen, J A; Thijs, L; Fagard, R H; Birkenhäger, W H; Arabidze, G; Babeanu, S; Gil-Extremera, B; Bulpitt, C J; Davidson, C; de Leeuw, P W; Efstratopoulos, A D; Fletcher, A E; Fogari, R; Jääskivi, M; Kawecka-Jaszcz, K; Nachev, C; Petrie, J C; Seux, M L; Tuomilehto, J; Webster, J; Yodfat, Y.
Afiliación
  • Staessen JA; Klinisch Laboratorium Hypertensie, Inwendige Geneeskunde-Cardiologie, UZ Gasthuisberg, Herestraat 49, B-3000 Leuven,Belgium. jan.staessen@med.kuleuven.ac.be
Hypertension ; 32(3): 410-6, 1998 Sep.
Article en En | MEDLINE | ID: mdl-9740604
In the double-blind Systolic Hypertension in Europe (Syst-Eur) Trial, active treatment was initiated with nitrendipine (10 to 40 mg/d) with the possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d) titrated or combined to reduce sitting systolic blood pressure by at least 20 mm Hg to <150 mm Hg. In the control group, matching placebos were used similarly. In view of persistent concerns about the use of calcium channel blockers as first-line antihypertensive drugs, this report explored to what extent nitrendipine, administered alone, prevented cardiovascular complications. Age at randomization averaged 70.2 years and systolic/diastolic blood pressure 173.8/85.5 mm Hg. Of 2398 actively treated patients, 1327 took only nitrendipine (average dose, 23.4 mg/d), and 1042 progressed to other treatments including nitrendipine (n=757; 35.7 mg/d), enalapril (n=783; 13.4 mg/d), and/or hydrochlorothiazide (n=294; 21.0 mg/d). Compared with the whole placebo group (n=2297), patients receiving monotherapy with nitrendipine had 25% (P=0.05) fewer cardiovascular end points, and those progressing to other active treatments showed decreases (P
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bloqueadores de los Canales de Calcio / Enalapril / Nitrendipino / Hidroclorotiazida / Hipertensión Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Hypertension Año: 1998 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bloqueadores de los Canales de Calcio / Enalapril / Nitrendipino / Hidroclorotiazida / Hipertensión Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Hypertension Año: 1998 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos